FDAHealthFebruary 13, 2026
Harbin Jixianglong Biotech Co., Ltd. — Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50
⚠️ CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution
Is this relevant to me?
- Geography
- Nationwide
- Source agency
- FDA
- Category
- Health
- Published
- February 13, 2026
Nationwide within the United States
What's affected?
- Product
- Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04 Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China
- Lot code
- CP-030-20250711
Additional details
Lot #: CP-030-20250711, Exp. Date Jul. 24th, 2027
What should I do?
Recommended action
Class II recall. Voluntary: Firm initiated Quantity affected: N/A.
Get Health recall alerts
Delivered to your inbox. Free. No account required.